Table 2 Inappropriate prescriptions by the patient’s eGFR: types of IP and drugs more involved in the medication plan of patients with CKD
Total number of IP, n | 201 |
Number of IP per patient, mean ± SD | 0.7 ± 1.0 |
Number of IP per patient, n (%) | |
0 | 139 (50.9) |
1 | 89 (32.6) |
2 | 30 (11.0) |
3 | 11 (4.0) |
4 | 1 (0.4) |
5 | 3 (1.1) |
Patients with any IP, n, (%) | 134 (49.1) |
Type of IP, n (%) | 201 (100.0) |
Inappropriate dose and/or frequency | 158 (78.6) |
Contraindicated drug | 28 (13.9) |
Inappropriate presentation (it contains a higher dose/intake than recommended according to the patient’s FGe) | 15 (7.5) |
Drugs more involved in IP, n (%) | |
According to ATC code | |
Lipid modifying agents, plain (C10A) | 45 (22.4) |
Other analgesics and antipyretics (N02B) | 44 (21.9) |
Angiotensin converting enzyme inhibitors, plain (C09A) | 33 (16.4) |
Blood glucose lowering drugs, excluding insulins (A10B) | 19 (9.4) |
Benzodiazepine derivatives (N05CD) | 14 (7.0) |
Preparations inhibiting uric acid production (M04AA) | 11 (5.5) |
Mineral supplements: calcium (A12A) plus Vitamin D and analogues (A11CC) | 5 (2.5) |
Antidepressants (N06A) | 5 (2.5) |
Others | 25 (12.4) |
According to active substance with respect to the total IP | |
Paracetamol | 43 (21.4) |
Atorvastatin | 28 (13.9) |
Enalapril | 28 (13.9) |
Fenofibrate | 15 (7.5) |
Lormetazepam | 14 (7.0) |
Metformin | 10 (5.0) |
Allopurinol | 9 (4.5) |
Sitagliptin | 8 (4.0) |
Others drugs | 46 (22.8) |
According to active substance with respect to the total number of patients’ study with the prescribed drug | |
Rosuvastatin | 2/2 (100.0) |
Fenofibrate | 15/16 (93.8) |
Lormetazepam | 14/16 (87.5) |
Alfuzosin | 4/5 (80.0) |
Cetirizine | 3/4 (75.0) |
Atorvastatin | 28/48 (58.3) |
Sitagliptin | 8/19 (42.1) |
Enalapril | 28/79 (35.4) |
Paracetamol | 43/125 (34.4) |
Allopurinol | 9/49 (18.4) |
Citalopram | 5/29 (17.2) |
Metformin | 10/59 (16.9) |